Sanifit Overview

  • Year Founded
  • 2007

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 31

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $236M

  • Investors
  • 1

Sanifit General Information

Description

Operator of a clinical-stage biopharmaceutical company intended to focus on treatments for progressive vascular calcification disorders. The company's drugs treat cardiovascular diseases linked to calcification in the end-stage renal disease population undergoing hemodialysis, thereby enabling patients on dialysis to be treated for heart disease.

Contact Information

Website
www.sanifit.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • ParcBIT - Ctra. Valldemossa
  • Km 7.4, Building Europa, 2nd Floor
  • 07121 Palma
  • Spain
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
Vertical(s)
Corporate Office
  • ParcBIT - Ctra. Valldemossa
  • Km 7.4, Building Europa, 2nd Floor
  • 07121 Palma
  • Spain

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Sanifit Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
15. Merger/Acquisition 22-Nov-2021 $236M Completed Generating Revenue
14. Later Stage VC 18-Nov-2020 Completed Generating Revenue
13. Debt - General 06-Aug-2020 Completed Generating Revenue
12. Later Stage VC (Series D) 26-Jun-2019 Completed Generating Revenue
11. Later Stage VC (Series C) 16-Nov-2018 Completed Generating Revenue
10. Later Stage VC 11-Oct-2017 Completed Generating Revenue
9. Later Stage VC 21-Oct-2016 Completed Generating Revenue
8. Later Stage VC (Series C) 08-Sep-2015 Completed Generating Revenue
7. Later Stage VC (Series B) 21-Aug-2014 $4.82M $5.25M Completed Generating Revenue
6. Grant 01-Jan-2014 $431K Completed Generating Revenue
To view Sanifit’s complete valuation and funding history, request access »

Sanifit Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary
Ordinary
Series D
Series C
Ordinary
Ordinary 24,411,518 $0.011795 $1.26 $1.26 1x $1.26 21.54%
Series B 4,246,263 $0.011795 $1 $1 1x $1 3.75%
To view Sanifit’s complete cap table history, request access »

Sanifit Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a clinical-stage biopharmaceutical company intended to focus on treatments for progressive vascular calcific
Drug Discovery
Palma, Spain
31 As of 2021

South San Francisco, CA
 

Cambridge, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Sanifit Competitors (73)

One of Sanifit’s 73 competitors is Cytokinetics, a Formerly VC-backed company based in South San Francisco, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Cytokinetics Formerly VC-backed South San Francisco, CA
Walden Biosciences Venture Capital-Backed Cambridge, MA
Prothena Corporation Dublin, Ireland
uniQure Formerly VC-backed Amsterdam, Netherlands
Geron Formerly VC-backed Foster City, CA
You’re viewing 5 of 73 competitors. Get the full list »

Sanifit Patents

Sanifit Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025162971-A1 Substituted ip5 compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification Pending 31-Jan-2024
US-20260337212-A1 Ip4-4,6 substituted derivative compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification Pending 29-Jul-2022
WO-2024023359-A1 Ip4-4,6 substituted derivative compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification Inactive 29-Jul-2022
US-20260337211-A1 Ip5 substituted compounds Pending 29-Jul-2022
WO-2024023360-A1 Ip5 substituted compounds Inactive 29-Jul-2022 C07F9/117
To view Sanifit’s complete patent history, request access »

Sanifit Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Sanifit Former Investors (19)

Investor Name Investor Type Holding Investor Since Participating Rounds
Alta Life Sciences Venture Capital Minority
Andera Partners PE/Buyout Minority
Baxter Ventures Corporate Venture Capital Minority
Caixa Capital Risc Corporate Venture Capital Minority
Columbus Venture Partners Venture Capital Minority
You’re viewing 5 of 19 investors. Get the full list »

Sanifit FAQs

  • When was Sanifit founded?

    Sanifit was founded in 2007.

  • Where is Sanifit headquartered?

    Sanifit is headquartered in Palma, Spain.

  • What is the size of Sanifit?

    Sanifit has 31 total employees.

  • What industry is Sanifit in?

    Sanifit’s primary industry is Drug Discovery.

  • Is Sanifit a private or public company?

    Sanifit is a Private company.

  • What is the current valuation of Sanifit?

    The current valuation of Sanifit is .

  • What is Sanifit’s current revenue?

    The current revenue for Sanifit is .

  • How much funding has Sanifit raised over time?

    Sanifit has raised $238M.

  • Who are Sanifit’s investors?

    Alta Life Sciences, Andera Partners, Baxter Ventures, Caixa Capital Risc, and Columbus Venture Partners are 5 of 19 investors who have invested in Sanifit.

  • Who are Sanifit’s competitors?

    Cytokinetics, Walden Biosciences, Prothena, uniQure, and Geron are some of the 73 competitors of Sanifit.

  • When was Sanifit acquired?

    Sanifit was acquired on 22-Nov-2021.

  • Who acquired Sanifit?

    Sanifit was acquired by CSL Vifor.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process